title: [Primary therapy of advanced ovarian carcinoma: current status and perspectives].
abstract: Standard therapy of advanced ovarian cancer includes staging laparotomy with aggressive debulking, possibly pelvic and para-aortic lymphadenectomy, and postoperative chemotherapy. Until present, combination chemotherapy with cis-/carboplatin and cyclophosphamide has been standard. Due to the positive results emerging from recent clinical trials, paclitaxel in combination with platinum might soon emerge as a new standard for patients with advanced ovarian cancer. The role of high-dose chemotherapy is currently under investigation. Pretherapeutic chemosensitivity testing, using a third-generation assay, is studied in randomized trials. Since the cost/benefit ratio is increasingly playing an important role, a cost comparison of the six most commonly used chemotherapy protocols is presented.
authors: Departement Frauenheilkunde, Universitätsspital Zürich.
authors: O R
authors: OR
authors: Köchli
authors: A
authors: A
authors: Barth
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D010052:Ovariectomy
vernacular_title: Primärtherapie des fortgeschrittenen Ovarialkarzinoms: Standortbestimmung und Perspektiven.